The US Food and Drug Administration has approved a major reduction in the recommended monitoring period for the first two doses of Amgen’s IMDELLTRA (tarlatamab-dlle), potentially making the treatment easier to administer in community oncology settings.

 

Under the updated prescribing information, patients receiving IMDELLTRA will now be monitored for 6 to 8 hours from the start of their first two infusions, down sharply from the previously recommended 22 to 24 hours.

 

Patients will also undergo a follow-up assessment, including vital signs, the day after each of those initial doses.

 

The change applies to adults with extensive-stage small cell lung cancer (ES-SCLC) whose disease has progressed on or after platinum-based chemotherapy.

 

For patients and caregivers, the FDA update could mean substantially less time spent in a healthcare setting during the opening phase of treatment. For community oncology practices, it could also simplify the logistics of administering the drug.

 

"People being treated for small cell lung cancer are already navigating an aggressive and difficult-to-treat disease, and the time required to receive and monitor treatment can add to that burden for both patients and care centers," said Jay Bradner, executive vice president, Research and Development, Artificial Intelligence and Data at Amgen. 

 

"This approval is an important step in simplifying care for people living with and treating ES-SCLC. Reducing monitoring to 6-8 hours for the initial doses may help address practical barriers associated with administering IMDELLTRA and enable more patients to receive care closer to home. We continue to work closely with the healthcare community to ensure appropriate educational support for navigating IMDELLTRA treatment is available to providers, patients and care partners."

 

The impact could be particularly relevant for community oncology, where an estimated 80% to 85% of U.S. cancer patients receive care.

 

"In community oncology, we care for patients where they live, and for people living with small cell lung cancer, that matters," said David M. Waterhouse, medical oncologist/hematologist at Oncology Hematology Care in Cincinnati, OH. 

 

"These patients are often very sick, and traveling long distances or spending extended time in a healthcare setting can be difficult for them and their families. Reducing the required monitoring period may make IMDELLTRA more feasible to administer in community practices, helping more patients receive treatment in their local care network and spend less time away from their support systems."

 

 

The FDA update is limited to the first two doses.

 

Patients will now receive 6 to 8 hours of monitoring from the start of infusion on Cycle 1 Day 1 and Cycle 1 Day 8, followed by assessments on Cycle 1 Days 2 and 9.

 

Monitoring requirements later in treatment remain unchanged: Cycle 1 Day 15 and throughout Cycle 2: 6 to 8 hours. Cycles 3-4: 3 to 4 hours. Cycle 5 and subsequent doses: 2 hours

 

Patients are also advised to remain within one hour of an appropriate healthcare setting for a total of 48 hours from the start of the infusion after the Cycle 1 Day 1 and Day 8 doses, accompanied by a caregiver.